These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29452665)

  • 1. Novel agents for relapsed and refractory follicular lymphoma.
    Cheah CY; Fowler NH
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for follicular lymphoma.
    Sorigue M; Ribera JM; Motlló C; Sancho JM
    Leuk Res; 2016 Oct; 49():38-46. PubMed ID: 27541051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
    Seiler T; Hiddemann W; Dreyling M
    Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory Agents in Follicular Lymphoma.
    Ysebaert L; Morschhauser F
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.
    Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H
    Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
    Fowler N
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
    Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
    Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When to treat patients with relapsed follicular lymphoma.
    Cheah CY; Seymour JF
    Expert Rev Hematol; 2017 Mar; 10(3):187-191. PubMed ID: 28164722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for follicular lymphoma.
    Maloney DG
    Curr Hematol Rep; 2003 Jan; 2(1):13-22. PubMed ID: 12901150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Follicular lymphoma].
    Illés A; Krenács L; Borbényi Z
    Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of microenvironment in follicular lymphoma.
    Nowakowski GS; Ansell SM
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):169-73. PubMed ID: 25696851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining the management of relapsed or refractory follicular lymphoma.
    Pagel JM; Burke JM; Leslie LA
    Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.